Hematology

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Conditions:   Rheumatoid Arthritis;   Arthritis, Rheumatoid
Interventions:   Biological: GSK3196165;   Drug: Tofacitinib 5 mg;   Drug: Placebo to GSK3196165;   Drug: Placebo to tofacitinib;   Drug: Methotrexate;   Drug: Folic (or folinic) acid
Sponsors:   GlaxoSmithKline;   IQVIA
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2019Comments OffActive | Arthritis | Efficacy | GSK3196165 | Inadequate | Methotrexate | Moderately | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Tofacitinib | Versus
Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant

Conditions:   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cord Blood Transplant Recipient;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
Intervention:   Biological: Recombinant Interleukin-7
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2019Comments OffAfter | Blood | Cord | Human | Interleukin7 | Promote | Recombinant | Recovery | Tcell | Transplant
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Condition:   Breast Cancer
Intervention:   Drug: Rucaparib
Sponsor:   University of Arizona
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2019Comments OffAffect | Breast | Expression | Inhibitor | Negative | Opportunity | PARP | PDL1 | Rucaparib | Trial | Triple | Tumors | Window
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors

Condition:   Prostate Cancer
Intervention:   Behavioral: Guided Lifestyle Program Intervention
Sponsors:   Medical College of Wisconsin;   Loyola University Chicago;   Marquette University;   University of Illinois at Chicago
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2019Comments OffAfricanAmerican | Cancer | Forward | Lifestyle | Moving | Program | Prostate | Survivors
Mechanism of Action Underlying Ketamine s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Conditions:   Depression;   Major Depressive Disorder;   Major Depression
Interventions:   Drug: Ketamine;   Drug: Perampanel;   Other: Placebo
Sponsor:   National Institute of Mental Health (NIMH)
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 4, 2019Comments OffAction | AMPA | Antidepressant | Depression | Effects | Ketamine | Major | Mechanism | Patients | Theory | Throughput | TreatmentResistant | Underlying
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Condition:   Arthritis, Rheumatoid
Interventions:   Biological: GSK3196165;   Drug: Tofacitinib;   Drug: Placebo to GSK3196165;   Drug: Placebo to Tofacitinib;   Drug: csDMARDs
Sponsors:   GlaxoSmithKline;   IQVIA
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019Comments OffActive | Antirheumatic | Arthritis | Conventional | cs/Biologic | Disease | DMARDs | Drugs | Efficacy | GSK3196165 | Inadequate | Moderately | Modifying | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Synthetic | Tofacitinib | Versus
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Conditions:   Chronic Lymphocytic Leukemia;   Loss of Chromosome 17p
Interventions:   Drug: Ibrutinib;   Drug: Venetoclax
Sponsors:   Kerry Rogers;   National Cancer Institute (NCI);   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 2, 2019Comments OffAfter | Chronic | Ibrutinib | Leukemia | Lymphocytic | Patients | Resistance | Treating | Venetoclax
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Condition:   Multiple Sclerosis, Relapsing-Remitting
Interventions:   Drug: BIIB017 (peginterferon beta-1a);   Drug: Interferon beta type 1a
Sponsor:   Biogen
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 1, 2019Comments OffBeta1a | BIIB017 | Efficacy | Evaluate | Multiple | Participants | Pediatric | PegInterferon | Relapsingremitting | Safety | Sclerosis | Study | Tolerability | Treatment